Get the Stockscreener App
12.88
6.62%
0.80
After Hours:
12.88
Eyepoint Inc stock is traded at $12.88, with a volume of 1.47M.
It is up +6.62% in the last 24 hours and up +4.29% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$12.08
Open:
$12.08
24h Volume:
1.47M
Relative Volume:
1.54
Market Cap:
$1.08B
Revenue:
$7.62M
Net Income/Loss:
$-271.60M
P/E Ratio:
-3.6781
EPS:
-3.5018
Net Cash Flow:
$-271.54M
1W Performance:
+9.43%
1M Performance:
+4.29%
6M Performance:
-23.92%
1Y Performance:
+44.72%
1-Day Range:
$12.05
$13.08
1-Week Range:
$11.58
$13.33
52-Week Range:
$7.94
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
12.88 | 1.01B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
New hires at EyePoint receive 39,700 stock options package - Stock Titan
(EYPT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus - AD HOC NEWS
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EYPT: Phase III retinal drug aims for six-month dosing, rapid vision gains, and commercial readiness - TradingView
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance - MSN
COMMODORE CAPITAL LP Increases Stake in EyePoint Inc - GuruFocus
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts - Investing.com
(EYPT) Risk Channels and Responsive Allocation - Stock Traders Daily
EyePoint Pharmaceuticals eyes transformative 2026 as DURAVYU Phase 3 data nears - MSN
EYPT: DURAVYU nears pivotal phase III readouts, targeting reduced treatment burden and strong safety - TradingView
Commodore Capital (EYPT) discloses 4.25M-share, 5.1% stake in EyePoint - Stock Titan
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint (NASDAQ: EYPT) CFO exercises RSUs, uses shares to cover tax - Stock Titan
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - Yahoo Finance
EYPT: DURAVYU's pivotal trial results are imminent, targeting six-month dosing and market differentiation - TradingView
EYPT: DURAVYU Phase III data expected in August, targeting six-month dosing and U.S. launch in 2025 - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
EyePoint Inc. (EYPT) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnnual Financial Report - The Legal Advocate
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
EyePoint hands new hires 158,100 stock options at $12.35 - Stock Titan
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
EyePoint: DURAVYU's Durability Could Drive Significant Upside (NASDAQ:EYPT) - Seeking Alpha
Adage Capital files amendment: 3,300,000 shares in EyePoint (EYPT) disclosed - Stock Titan
TradingKey - TradingKey
Liquidity Mapping Around (EYPT) Price Events - Stock Traders Daily
EyePoint Pharmaceuticals stock (US30233B1098): Trading at discount to fair value estimates - AD HOC NEWS
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyepoint Inc Stock (EYPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Option Exercise |
8.26 |
2,437 |
20,130 |
2,437 |
| Ribeiro Ramiro | Chief Medical Officer |
Apr 17 '26 |
Sale |
15.00 |
2,437 |
36,555 |
0 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):